Immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC; translational correlatives from a mature randomized phase II trial.
NCTXXXXXX was a phase II prospective trial in which non-small lung cancer patients were randomized to local consolidative therapy (LCT) versus maintenance therapy or observation (MT/O). Peripheral blood from patients enrolled on NCTXXXXXX were labelled as 1) baseline, 2) early follow-up (FU) if obtained in the 1st or 2nd FU evaluation (6-18 weeks), and 3) late FU if obtained in the 3rd to 6th FU evaluations (22-50 weeks). All LCT patients included in this analysis received radiation. Among 49 randomized patients, 21 underwent T-cell CDR3 variable region sequencing utilizing immunoSEQ, 31 patients underwent ctDNA analysis via next generation sequencing with a 1,021 cancer gene panel, and cytokine concentration was assayed in 19 patients utilizing ELISA. All analyses were exploratory and not corrected for multiple testing. No associations were identified between baseline T-cell repertoire and ctDNA metrics with patient outcomes. Among baseline cytokines, IL 1α was the only cytokine associated with both OS (HR=0.02, 95% CI: 0.1-0.5, P=0.0006) and PFS (HR=0.5, 95% CI: 0.2-0.9, P=0.03). At early FU, LCT was associated with decreased ctDNA burden including lower number of detected mutations (median: 2 [interquartile range, IQR: 1-6] vs. 6 [IQR: 4-18]) and decreased average variable allele frequency (VAF; median: 0.006 [IQR: 0.003-0.010] vs. 0.011 [IQR: 0.007-0.014]) compared with MT/O. Among 6 patients with serial ctDNA analysis, a rise in ctDNA detected mutation burden preceded clinical progression by 6.7 months. At early FU, LCT was associated with changes in T-cell clonality that suggested oligoclonal expansion, specifically increased T-cell clonality (median: 0.15 [IQR: 0.12-0.24] vs. 0.10 [IQR: 0.05-0.13])) and frequency of top 10 clones (median: 0.14 [IQR: 0.06-0.18] vs 0.21[IQR: 0.19-0.28])). LCT was associated with decreased ctDNA burden and oligoclonal expansion at early FU timepoints. Baseline IL 1α was associated with improved patient outcomes.